Lagatar24 Desk
New Delhi, Oct 27: The World Health Organization (WHO) has sought more information and additional clarification from Bharat Biotech regarding the Indian vaccine of Corona, Covaxin.
“Technical Advisory Group (TAG) for emergency use listing has decided that additional clarification from the manufacturers are needed to conduct a final EUL risk benefit assessment for global use of the vaccine,” the WHO said on a decision regarding the emergency use listing of covaxin.
Before Tuesday’s meeting of the WHO’s Technical Advisory Group, it was said that if it is satisfied, then a decision can be taken about Covaxin only in the next 24 hours. Now the next meeting of this group will be held on November 3, in which the final assessment will be done regarding the global use of Covaxin.
“TAG expects to receive these clarifications from the manufacturer by the end of this week and aims to reconvene for the final risk benefit assessment on Wednesday,November3”, the WHO added.
Notably, Covaxin from WHO on 19 April, but it is still pending. In such a situation, people taking Covaxin are not able to travel abroad. Once approved, it can be used as a vaccine passport. Also Bharat Biotech will be able to easily export it worldwide. Covaxin has been approved in 13 countries so far and it is India’s first indigenous COVID-19 vaccine, developed by Hyderabad based Bharat Biotech in collaboration with the Indian Council of Medical Research.
